Clinical Trial Update: ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu [EARLY_Phase 1]

View source ↗

Summary

Early-phase trial update on ProofPrincip intra-tumoral T cells with a single-dose checkpoint inhibitor for gastroesophageal adenocarcinoma with ARID1A mutation;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Gastric Adenocarcinoma

Drugs mentioned

• ProofPrincip IntraTu TCells (intra-tumoral T cell therapy)
• Unspecified checkpoint inhibitor (checkpoint inhibitor)

Snippet

Sponsor: University of California, Irvine | Conditions: Solid Tumor, Adult, Malignant Solid Tumor | EARLY_Phase 1 | Status: NOT_YET_RECRUITING